eligibility_summary
Eligibility: Adults with mesothelin+ pleural malignancy suitable for cytoreductive surgery + intrapleural perfusion. Biphasic MPM <50% sarcomatoid, extrathoracic MPE controlled, stage IV pleural cancers post–1L SOC, MPM untreated. ECOG <2, adequate lung/organ function, O2 ≥90%, stable treated brain mets, contraception, controlled HBV/HCV, consent+tissue, 06C0014 required. Exclude: active smoking, significant steroids, recent therapy/trials, LMB‑100/SS1P allergy, major CV disease, pneumonitis, immunosuppressed transplant, uncontrolled HIV/COVID/infections, active 2nd cancer, pregnancy, uncontrolled illness/psychiatric.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: LMB-100 immunotoxin (biologic protein) delivered as a single 90‑min normothermic intrapleural perfusion immediately after cytoreductive surgery, mesothelin IHC for selection. Mechanism: LMB‑100 is a recombinant humanized anti‑mesothelin Fab fused to de‑immunized Pseudomonas exotoxin A, after mesothelin binding and internalization, the toxin ADP‑ribosylates EF‑2, halting protein synthesis and inducing tumor cell death. Targets: mesothelin‑expressing tumor cells on pleural surfaces (epithelioid MPM and mesothelin‑positive pleural metastases). Pathways: mesothelin-mediated uptake, translational machinery (EF‑2). Status: Phase I, withdrawn.